The expanded CE certification includes NeuroQuant, the latest generation of the company’s quantitative neuroimaging platform, which provides automated brain segmentation, volumetric analysis, and longitudinal tracking to support assessment and monitoring of Alzheimer’s disease, multiple sclerosis, traumatic brain injury, epilepsy, and other neurological conditions. NeuroQuant Brain Tumor offers advanced quantitative imaging to support visualization, assessment, and longitudinal monitoring of brain tumors. OnQ Prostate provides Advanced Restriction Spectrum Imaging-based quantitative maps to help improve detection, localization, and assessment of clinically significant prostate cancer.